However, patients with TP53-mutated AML treated during the initial noncomparative study of azacitidine/decitabine + venetoclax had a 47% rate of CR/CRi [7]; an unplanned and underpowered post hoc subgroup analysis of VIALE-A showed no clear benefit in the OS when evaluating 52 patients with TP53m-AML (hazard ratio (HR) = 0.76, 95% CI: 0.40–1.45) [36]. This evidence concerns the gene TP53 and acute myeloid leukemia.